Hematopoietic Cell Transplants for Waldenström Macroglobulinemia
- 1 June 2017
- book chapter
- book charpter
- Published by Cambridge University Press (CUP)
Abstract
No abstract availableThis publication has 49 references indexed in Scilit:
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood, 2014
- Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemiaBlood, 2014
- Proceedings of the Seventh International Workshop on Waldenström MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2013
- microRNA Aberrations in Waldenström MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2013
- Prognostication in Young and Old Patients with Waldenström's Macroglobulinemia: Importance of the International Prognostic Scoring System and of Serum Lactate DehydrogenaseClinical Lymphoma Myeloma and Leukemia, 2009
- Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experienceBone Marrow Transplantation, 2007
- Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001Blood, 2006
- Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)Leukemia & Lymphoma, 2004
- Peripheral neuropathy in macroglobulinemiaNeurology, 1987